Brepocitinib (Compound 23; 3-30 mg/kg; oral administration; for 7 consecutive days; female Lewis rats) treatment significantly reduces paw volume increase in a dose-dependent manner. The plasma concentrations in animals dosed with Brepocitinib at peak (30 min) and trough (24 h) time intervals post final dose respectively are as follows: 3 mg/kg, 3.54 μM, 0.0221 μM; 10 mg/kg, 10.95 μM, 0.06 μM; and 30 mg/kg, 23.89 μM, 0.06 μM[1].
| Animal Model: | Female Lewis rats with induced arthritis[1] |
| Dosage: | 3 mg/kg, 10 mg/kg, or 30 mg/kg |
| Administration: | Oral administration; for 7 consecutive days |
| Result: | Increased in paw volume was significantly lower and dose-dependent.
|
